Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients

Journal of Endocrinological Investigation

Volumn 28, Issue 2, 2005, Pages 965-972

  Guang Da, X ^a   Hui Ling, S ^a   Zhi Song, C ^a   Lin Shuang, Z ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Hypothyroidism; Osteoprotegerin

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; OSTEOPROTEGERIN; THYROTROPIN; THYROXINE;

ADULT; ARTERY DILATATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; PARAMETER; PROTEIN BLOOD LEVEL; THYROID FUNCTION; VASCULAR ENDOTHELIUM;

EID: 33144480672     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345333     Document Type: Article

References (25)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309-19.
2. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin - clinical relevance and potential applications. Eur J Endocrinol 2001, 145: 681-3.
3. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86: 631-7.
4. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21: 1998-2003.
5. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12: 1260-8.
6. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002, 521: 180-4.
7. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol 2000, 275: 20959-62.
8. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106: 1192-4.
9. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 2000, 132: 270-8.
10. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000, 10: 665-79.
11. Wren JC. Thyroid function and coronary atherosclerosis. J Am Geriatr Soc 1968, 16: 696-704.
12. Nagasaki T, Inaba M, Jono S, et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol, 2005, 152: 347-53.
13. Guangda X, Yuhua W. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia 2003, 46: 514-9.
14. Guangda X, Yunlin W. Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care 2004, 27: 801-2.
15. Papaioannou GI, Lagasse M, Mather JF, Thompson PD. Treating hypothyroidism improves endothelial function. Metabolism 2004, 53: 278-9.
16. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003, 88: 3731-7.
17. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192: 463-74.
18. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001, 358: 257-9.
19. Nagasaki T, Inaba M, Henmi Y, et al. Decrease in carotid intima-media thicknes in hypothyroid patients after normalization of thyroid function. Clin Endocrinol (Oxf) 2003, 59: 607-12.
20. Cappola A, Laddenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003, 88: 2438-44.
21. Cooper DS. Clinical practice. Suclinical hypothyroidism. N Engl J Med, 2001, 345: 260-5.
22. Hofbauer LC, Kluger S, Kuhne CA, et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 2002, 86: 642-50.
23. Amato G, Mazziotti G, Sorvillo F, et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004, 35: 785-91.
24. 3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 2004, 74: 382-7.
25. Engler H, Riesen W. Effect of thyroid function on concentration of lipoprotein (a). Clin Chem 1993, 39: 2466-9.